<DOC>
	<DOCNO>NCT02471716</DOCNO>
	<brief_summary>This phase 1/2 single arm , open-label , safety , tolerability , PK study FPA008 PVNS/dt-TGCT patient . Patients enrol either Phase 1 ( dose escalation ) Phase 2 ( dose expansion ) study , .</brief_summary>
	<brief_title>Study FPA008 Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor</brief_title>
	<detailed_description />
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Synovitis , Pigmented Villonodular</mesh_term>
	<criteria>Histologically confirm diagnosis inoperable PVNS/ dtTGCT potentially resectable tumor would result unacceptable functional loss morbidity determine qualified surgeon multidisciplinary tumor board ( must document CRF screen ) Measurable PVNS/dtTGCT RECIST 1.1 MRI ECOG performance status &lt; 1 Prior therapy antiCSF1R antibody Prior therapy PLX3397 unless discontinue intolerance ( i.e. , nonprogression prior kinase inhibitor ) CK liver function test ( include ALT , AST , total bilirubin ) , outside range local laboratory normal Screening Inadequate organ bone marrow function History congestive heart failure myocardial infarction &lt; 1 year prior first study dose administration Significant abnormalities ECG Screening Contraindications MRI use intravenous gadoliniumbased contrast agent Positive test latent TB Screening ( Quantiferon test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diffuse Type Tenosynovial Giant Cell Tumor ( dt-TGCT )</keyword>
</DOC>